518044-36-5 Usage
Uses
Used in Pharmaceutical Industry:
Mal-PEG5-t-butyl ester is used as a PEGylation agent for improving the pharmacokinetic properties of therapeutic biomolecules. The PEG chain increases solubility, stability, and circulation time in the body, while the maleimide group enables site-specific conjugation to biomolecules with thiol groups.
Used in Drug Delivery Systems:
In the field of drug delivery, Mal-PEG5-t-butyl ester serves as a versatile linker for the development of targeted drug delivery systems. The maleimide group can be used to attach drug molecules or targeting ligands to drug carriers, such as nanoparticles or liposomes, allowing for specific and efficient delivery to desired sites within the body.
Used in Bioconjugation:
Mal-PEG5-t-butyl ester is used as a bioconjugation agent for the covalent attachment of various biomolecules, such as proteins, peptides, or nucleic acids, to other molecules or surfaces. The maleimide group provides a selective and stable linkage to thiol-containing biomolecules, facilitating the creation of novel bioconjugates for research and therapeutic applications.
Used in Diagnostics:
In the diagnostics industry, Mal-PEG5-t-butyl ester can be employed as a component in the development of imaging agents or biosensors. The PEG chain can improve the biocompatibility and solubility of these agents, while the maleimide group allows for the specific attachment of diagnostic molecules, such as fluorescent dyes or radioactive isotopes, to biomolecular targets.
Check Digit Verification of cas no
The CAS Registry Mumber 518044-36-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,8,0,4 and 4 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 518044-36:
(8*5)+(7*1)+(6*8)+(5*0)+(4*4)+(3*4)+(2*3)+(1*6)=135
135 % 10 = 5
So 518044-36-5 is a valid CAS Registry Number.
518044-36-5Relevant academic research and scientific papers
CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS
-
, (2016/10/04)
The present invention relates to antibody- or peptide-drug conjugate compounds where one or more cryptophycin derivatives (macrocyclic depsipeptide) are covalently attached by a self-immolative linker which binds to one or more tumor-associated antigens or cell-surface receptors. The linker contains a cleavage site for proteases and a dipeptide unit able to form a diketopiperazine. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders, such as immune or infective diseases.
